Legal & General Group
ELOX

Legal & General Group’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

Legal & General Group’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-76
Closed -$10K – 3721
2021
Q1 		$10K Hold
76
– – ﹤0.01% 3394
2020
Q4 		$12K Hold
76
– – ﹤0.01% 3289
2020
Q3 		$8K Sell
76
-26
-25% -$3.12K ﹤0.01% 3328
2020
Q2 		$12K Hold
102
– – ﹤0.01% 3276
2020
Q1 		$8K Sell
102
-33
-24% -$5.37K ﹤0.01% 3209
2019
Q4 		$40K Buy
135
+43
+47% +$8.66K ﹤0.01% 2912
2019
Q3 		$17K Hold
92
– – ﹤0.01% 3188
2019
Q2 		$37K Hold
92
– – ﹤0.01% 2921
2019
Q1 		$43K Hold
92
– – ﹤0.01% 2765
2018
Q4 		$44K Buy
92
+12
+15% +$6.62K ﹤0.01% 2743
2018
Q3 		$55K Hold
80
– – ﹤0.01% 2729
2018
Q2 		$55K Buy
+80
New +$51.9K ﹤0.01% 2705

Other funds holding ELOX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Legal & General Group's ELOX Position: Q2 2021 in Review

Legal & General Group sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q2 2021, closing a stake of 76 shares — an estimated $10K sold.

Legal & General Group first reported a position in ELOX in Q2 2018 and held it in 12 quarters. The position peaked at $55K in Q3 2018. 46 funds tracked by Wall St. Rank hold ELOX as of Q2 2021.

  • Legal & General Group reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 76 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $10K.
  • Legal & General Group first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 12 quarters.
  • Legal & General Group's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $55K in Q3 2018.
  • 46 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.